Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Julphar
Boehringer Ingelheim
QuintilesIMS
McKesson
Mallinckrodt
Argus Health
Colorcon
Fuji

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,818,226

« Back to Dashboard

Summary for Patent: 6,818,226
Title: Dermal penetration enhancers and drug delivery systems involving same
Abstract:A transdermal drug delivery system which comprises at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer; characterised in that the dermal penetration enhancer is a safe skin-tolerant ester sunscreen. A non-occlusive, percutaneous or transdermal drug delivery system which comprises: (i) an effective amount of at least one physiologically active agent or prodrug thereof; (ii) at least one non-volatile dermal penetration enhancer; and (iii) at least one volatile liquid; characterised in that the dermal penetration enhancer is adapted to transport the physiologically active agent across a dermal surface or mucosal membrane of an animal, including a human, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent or prodrug within said surface or membrane; and the dermal penetration enhancer is of low toxicity to, and is tolerated by, the dermal surface or mucosal membrane of the animal.
Inventor(s): Reed; Barry Leonard (Strathmore, AU), Morgan; Timothy Matthias (Parkville, AU), Finnin; Barrie Charles (Glen Iris, AU)
Assignee: ACRUX DDS Pty. Ltd. (Victoria, AU)
Application Number:09/910,780
Patent Claim Types:
see list of patent claims
Delivery; Compound; Use; Device;

Drugs Protected by US Patent 6,818,226

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ➤ Subscribe ➤ Subscribe Y TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE ➤ Subscribe
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN ➤ Subscribe
Perrigo Pharma Intl EVAMIST estradiol SPRAY;TRANSDERMAL 022014-001 Jul 27, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCCIATED WITH MENOPAUSE) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,818,226

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPN8144/96Feb 19, 1996

Non-Orange Book US Patents Family Members for Patent 6,818,226

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,438,203 Dermal penetration enhancers and drug delivery systems involving same ➤ Subscribe
6,299,900 Dermal penetration enhancers and drug delivery systems involving same ➤ Subscribe
6,998,138 Topical delivery of anti-alopecia agents ➤ Subscribe
6,929,801 Transdermal delivery of antiparkinson agents ➤ Subscribe
7,387,789 Transdermal delivery of non-steroidal anti-inflammatory drugs ➤ Subscribe
6,964,777 Transdermal delivery of antianxiety agents ➤ Subscribe
6,916,486 Transdermal delivery of analgesics ➤ Subscribe
6,916,487 Transdermal delivery of antiemetics ➤ Subscribe
6,923,983 Transdermal delivery of hormones ➤ Subscribe
8,071,075 Dermal penetration enhancers and drug delivery systems involving the same ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,818,226

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 324865 ➤ Subscribe
Austria 410136 ➤ Subscribe
Austria 472997 ➤ Subscribe
Australia 1713497 ➤ Subscribe
Australia 5258999 ➤ Subscribe
Australia 706967 ➤ Subscribe
Australia PN814496 ➤ Subscribe
Canada 2244089 ➤ Subscribe
Germany 122012000019 ➤ Subscribe
Germany 122012000020 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Covington
Cantor Fitzgerald
Cipla
Julphar
Express Scripts
Boehringer Ingelheim
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot